On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Stratec Biomedical AG Gemini. This instrumentation change is necessary as Bio-Rad is discontinuing service on our existing QuickStep instrumentation.
Although the Immucor assay and sample requirements will remain the same, the package insert has been modified to state the assay is specific to the Stratec Gemini instrument. The new package insert, assay history list, and platform history list will be available on the CTS website on 04/29/19.
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...